In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. Celastrol was determined like a Myb inhibitor that suppressed C/EBPβ activity and repressed https://jamesx110kwh3.fliplife-wiki.com/user